QIA.DE
Latest Trade
34.42EURChange
0.14(+0.41%)Volume
282,101Today's Range
-
34.4752 Week Range
-
39.19As of on the XETRA ∙ Minimum 15 minute delay
Previous Close | 34.28 |
|---|---|
Open | 34.40 |
Volume | 282,101 |
3M AVG Volume | 14.63 |
Today's High | 34.47 |
Today's Low | 34.21 |
52 Week High | 39.19 |
52 Week Low | 22.54 |
Shares Out (MIL) | 227.75 |
Market Cap (MIL) | 7,915.96 |
Forward P/E | -- |
Dividend (Yield %) | -- |
Qiagen Q4 Net Sales Up At $413.5 Million
Qiagen Builds On Global Collaboration With Amgen For Companion Diagnostic Development In Non-Small Cell Lung Cancer
Qiagen Says Concludes Strategic Alternatives Review
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Executive Leadership
Hakan Bjorklund
Independent Chairman of the Supervisory Board
Thierry Bernard
Interim Chief Executive Officer, Member of the Executive Committee
Roland Sackers
Managing Director, Chief Financial Officer, Member of the Executive Committee
Barthold Piening
Senior Vice President, Head of Global Operations, Member of the Executive Committee
Annette Koch
Senior Vice President and Chief Human Resources Officer, Member of the Executive Committee
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 5.62 |
Price To Book (MRQ) | 3.34 |
Price To Cash Flow (TTM) | 45.12 |
Total Debt To Equity (MRQ) | 67.27 |
LT Debt To Equity (MRQ) | 56.02 |
Return on Investment (TTM) | -0.92 |
Return on Equity (TTM) | -0.75 |
Epidemics are catastrophic for humans, and it turns out they aren’t much better for healthcare companies. The number of confirmed cases of the new coronavirus has multiplied more than 80-fold over three weeks despite measures such as travel bans, and exceeded 45,000 across...
Genetic testing specialist Qiagen <QIA.DE> should have a targeted test for the coronavirus ready this month and is extremely active in providing products to disease control institutions in China, its interim CEO said on Wednesday.
Genetic testing specialist Qiagen <QIA.DE> should have a targeted test for the coronavirus ready this month and is extremely active in providing products to disease control institutions in China, its interim CEO said on Wednesday.
The following are some of the factors that may move German stocks on Wednesday:
Genetic testing specialist Qiagen <QIA.DE> beat analysts' expectations for quarterly sales and profit growth on Tuesday, citing savings generated after its decision to stop developing new next-generation sequence (NGS) instruments.
Genetic testing specialist Qiagen beat analysts' expectations for quarterly sales and profit growth on Tuesday, citing positive outcomes after its decision to stop developing new next-generation sequence (NGS) instruments.
The following are some of the factors that may move German stocks on Tuesday:
Shares in genetic testing company Qiagen <QIA.DE> rose 3.6% on Monday after a report that the firm was talking to an interested party about a possible acquisition.
The following are some of the factors that may move German stocks on Tuesday:
European stocks wrapped up a holiday-thinned week at record highs on Friday as growing hopes that a Sino-U.S. trade deal would be inked soon, as well as the latest dose of upbeat China data supported prospects of an improving global growth.
European shares rose to another record high on Friday, as investors remained optimistic about an improving global economy after a fresh dose of upbeat economic data from China and firming indications of a preliminary U.S.-China trade deal.
The following are some of the factors that may move German stocks on Friday:
Genetic testing firm Qiagen NV <QIA.DE> <QGEN.N> said on Tuesday it has concluded a review of potential alternatives, including a sale of the company, and determined that continuing to be a stand-alone business is its best option.
Genetic testing firm Qiagen NV said on Tuesday it has concluded a review of potential alternatives, including a sale of the company, and determined that continuing to be a stand-alone business is its best option.
German health technology company Siemens Healthineers is not interested in a takeover of Qiagen, the genetic testing company which last month said it would start talks with several potential suitors.
European stocks ended flat on Monday as a spurt of defensive buying over uncertainty surrounding U.S.-China trade talks helped temper losses in the auto sector.
Qiagen NV <QGEN.O> shares jumped to their highest in almost 19 years on Monday after the German genetic testing company said it would start talks with several potential suitors.
A bidding war for Spanish bourse BME and gains in defensive stocks propped up European markets on Monday, although doubts on whether or not the United States will impose tariffs on EU carmakers weighed on shares.
European shares edged closer to a record level on Monday, as optimism around U.S.-China trade talks and a surprise move by China's central bank in cutting a key interest rate painted an upbeat picture about global growth.
The following are some of the factors that may move German stocks on Monday:
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.